JULIO BELARMINO
BOBES GARCIA
Investigador hasta 2022
![Foto de JULIO BELARMINO](/img/nophoto.png)
![Foto de Eli Lilly and Company](/img/noimage_org.png)
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (8)
2022
-
Mapping genomic loci implicates genes and synaptic biology in schizophrenia
Nature, Vol. 604, Núm. 7906, pp. 502-508
2012
-
Delphi consensus on the physical health of patients with schizophrenia: Evaluation of the recommendations of the Spanish societies of psychiatry and biological psychiatry by a panel of experts
Actas Espanolas de Psiquiatria, Vol. 40, Núm. 3, pp. 114-128
2011
-
Clinical meaningful outcomes in schizophrenia: Remission and recovery
Revista de Psiquiatria y Salud Mental, Vol. 4, Núm. 1, pp. 53-65
2007
-
Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study
European Psychiatry, Vol. 22, Núm. 8, pp. 490-498
2005
-
Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951
-
Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting
Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486
2003
-
Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481
-
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study
European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48